Seegene Inc (096530) - Total Liabilities

Latest as of September 2025: ₩214.46 Billion KRW ≈ $145.34 Million USD

Based on the latest financial reports, Seegene Inc (096530) has total liabilities worth ₩214.46 Billion KRW (≈ $145.34 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Seegene Inc - Total Liabilities Trend (2012–2024)

This chart illustrates how Seegene Inc's total liabilities have evolved over time, based on quarterly financial data. See Seegene Inc (096530) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.

Seegene Inc Competitors by Total Liabilities

The table below lists competitors of Seegene Inc ranked by their total liabilities.

Company Country Total Liabilities
Omnia Holdings Limited
JSE:OMN
South Africa ZAC8.43 Billion
EnTie Commercial Bank Ltd
TW:2849
Taiwan NT$352.10 Billion
Hefei Department Store Group Co Ltd
SHE:000417
China CN¥6.62 Billion
Hichain Logistics Co Ltd
SHE:300873
China CN¥1.51 Billion
Ziel Home Furnishing Technology Co. Ltd. A
SHE:301376
China CN¥2.89 Billion
Fujian Longxi Bearing Group Co Ltd
SHG:600592
China CN¥850.66 Million
Zhejiang Whwh
SHG:600576
China CN¥2.38 Billion
MHP SE GDR S/2
F:MPQ
Germany €2.52 Billion

Liability Composition Analysis (2012–2024)

This chart breaks down Seegene Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 096530 company net worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 4.83 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.21 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.18 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Seegene Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Seegene Inc (2012–2024)

The table below shows the annual total liabilities of Seegene Inc from 2012 to 2024.

Year Total Liabilities Change
2024-12-31 ₩223.80 Billion
≈ $151.67 Million
+1.24%
2023-12-31 ₩221.05 Billion
≈ $149.80 Million
-9.03%
2022-12-31 ₩243.01 Billion
≈ $164.68 Million
-40.49%
2021-12-31 ₩408.31 Billion
≈ $276.71 Million
-9.11%
2020-12-31 ₩449.26 Billion
≈ $304.46 Million
+940.74%
2019-12-31 ₩43.17 Billion
≈ $29.25 Million
+20.65%
2018-12-31 ₩35.78 Billion
≈ $24.25 Million
-10.10%
2017-12-31 ₩39.80 Billion
≈ $26.97 Million
-39.37%
2016-12-31 ₩65.65 Billion
≈ $44.49 Million
+11.35%
2015-12-31 ₩58.96 Billion
≈ $39.95 Million
+35.17%
2014-12-31 ₩43.62 Billion
≈ $29.56 Million
-2.19%
2013-12-31 ₩44.59 Billion
≈ $30.22 Million
+7.00%
2012-12-31 ₩41.68 Billion
≈ $28.24 Million
--

About Seegene Inc

KQ:096530 Korea Biotechnology
Market Cap
$900.01 Million
₩1.33 Trillion KRW
Market Cap Rank
#9537 Global
#259 in Korea
Share Price
₩28800.00
Change (1 day)
-2.37%
52-Week Range
₩21850.00 - ₩35150.00
All Time High
₩140042.88
About

Seegene, Inc. manufactures and sells molecular diagnostics products worldwide. It offers IVD products comprising respiratory disease detection products for respiratory infections; gastrointestinal disease detection products for gastrointestinal tract infections; human papillomavirus detection products; sexually transmitted infections causative pathogens detection products; tuberculosis detection … Read more